mRNA vaccines have changed the way we fight infectious diseases. Introducing Pfizer and BioNTech’s research study for an investigational COVID-19 and flu combination vaccine using mRNA technology.
Both COVID-19 and flu continue to be major public health concerns around the world. Recent advances in mRNA technology have made it possible to combine a COVID-19 booster vaccine and the annual flu vaccine into a single shot. A combination vaccine would be more convenient and accessible for most people and could help increase vaccination rates against both COVID-19 and flu each year.
This study will help us learn if different investigational mRNA combination vaccines are safe and can help the body produce antibodies which may help fight off different strains of flu as well as COVID-19.
This research study is enrolling adults who:
- Are 18 to 64 years old
- Are generally healthy or have stable chronic conditions
- Have not received a flu vaccine in the last six months
- Have received at least three prior doses of an mRNA COVID-19 vaccine (Pfizer-BioNTech or Moderna), and the last dose was a bivalent vaccine* given at least five months ago
*COVID-19 vaccine doses received after September 1, 2022 are considered bivalent in the U.S.There will be other study requirements that the study team will discuss with you.
This study will last for about six months and includes at least six study visits. Participants will receive one or two injections on the same day. There is no cost to participate, and reimbursement for any study-related expenses will be provided.
Ready to learn more?
Contact the study team: